Corona Remedies Limited, incorporated in August 2004, is a fast-growing pharmaceutical formulation company focused on the Indian market. The company develops, manufactures, and markets a wide range of branded products across women’s healthcare, cardio-diabeto, pain management, urology, and other key therapeutic segments, including vitamins/minerals/nutrition, gastrointestinal, and respiratory care.

As of December 2024, Corona’s portfolio comprised 67 brands, which expanded to 71 brands by MAT June 2025. Of these, 27 are “engine brands”, contributing over 72% of domestic sales. The company has built strong positions across chronic and sub-chronic therapies, which accounted for 70.10% of domestic revenues and grew at a notable 20.48% CAGR over the period.

Corona has established a strong commercial footprint through a pan-India marketing and distribution network, supported by 2,598–2,671 medical representatives across 22 states, enabling deep engagement with healthcare professionals and robust penetration across its targeted therapy areas. The company ranks 29th in the Indian Pharmaceutical Market (IPM) and 17th in covered markets.

The company operates two manufacturing facilities—one in Gujarat and another in Himachal Pradesh—backed by a strong focus on quality and current Good Manufacturing Practices (cGMP). As of December 31, 2024, Corona employed 88 R&D professionals, underpinning its commitment to developing differentiated pharmaceutical products and strengthening its innovation pipeline. Strategic acquisitions, such as Myoril from Sanofi, have further expanded its specialty portfolio.

Competitive Strengths

• One of the fastest-growing companies among the top 30 IPM players, with a 13.58% CAGR in domestic sales from MAT June 2024 to MAT June 2025, outpacing the IPM growth of 7.90%.
• Proven ability to build a broad, diversified brand portfolio, strengthened by high-performing “engine brands.”
• Extensive pan-India sales infrastructure and a marketing strategy focused on the high-potential “middle of the pyramid” segment.
• Quality-driven manufacturing capabilities and strong R&D focus enabling a pipeline of differentiated formulations.
• Experienced and entrepreneurial leadership team supported by marquee institutional investors.